These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9494064)

  • 21. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage.
    Fornai M; Natale G; Colucci R; Tuccori M; Carazzina G; Antonioli L; Baldi S; Lubrano V; Abramo A; Blandizzi C; Del Tacca M
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):79-87. PubMed ID: 16080005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.
    Schulz HU; Hartmann M; Steinijans VW; Huber R; Lührmann B; Bliesath H; Wurst W
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S51-7. PubMed ID: 8793603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
    Besancon M; Simon A; Sachs G; Shin JM
    J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pantoprazole does not interact with nifedipine in man under steady-state conditions.
    Bliesath H; Huber R; Steinijans VW; Koch HJ; Kunz K; Wurst W
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S81-5. PubMed ID: 8793608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of pantoprazole drug interactions in man.
    Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
    Int J Clin Pharmacol Ther; 1994 Aug; 32(8):385-99. PubMed ID: 7981922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
    Sachs G; Shin JM; Pratha V; Hogan D
    Drugs Today (Barc); 2003 Mar; 39 Suppl A():11-4. PubMed ID: 12712216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration.
    Ehrlich A; Lücker PW; Wiedemann A; Sander P; Huber R; Mascher H
    Methods Find Exp Clin Pharmacol; 1999; 21(1):47-51. PubMed ID: 10222447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of pantoprazole drug interactions in man: an updated review.
    Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S31-50. PubMed ID: 8793602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of pantoprazole drug interactions in man: an updated review.
    Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
    Int J Clin Pharmacol Ther; 1996 Jun; 34(6):243-62. PubMed ID: 8793611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
    Hartmann M; Huber R; Bliesath H; Steinijans VW; Koch HJ; Wurst W; Kunz K
    Int J Clin Pharmacol Ther; 1995 Sep; 33(9):481-5. PubMed ID: 8520804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and drug interactions--relevant factors for the choice of a drug.
    Zech K; Steinijans VW; Huber R; Kolassa N; Radtke HW
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S3-6. PubMed ID: 8793598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration.
    Bliesath H; Huber R; Hartmann M; Lühmann R; Wurst W
    Int J Clin Pharmacol Ther; 1994 Jan; 32(1):44-50. PubMed ID: 8199751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity.
    Parsons ME
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S15-20. PubMed ID: 8930575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
    Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
    Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
    Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
    Hartmann M; Huber R; Bliesath H; Steinijans VW; Koch HJ; Wurst W; Kunz K
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S67-71. PubMed ID: 8793605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The basis of differentiation of PPIs.
    Sachs G; Shin JM
    Drugs Today (Barc); 2004 Mar; 40 Suppl A():9-14. PubMed ID: 15190382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
    Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.